• This article examines whether Abbott Laboratories could be presenting a value opportunity after a difficult period in the market, and breaks down what the current share price might be offering.
• The stock last closed at US$87.01. Recent returns show a 4.2% decline over 7 days, a 14.6% decline over 30 days, and a 29.9% decline year to date, including a 33.7% decline over the past year. These moves mean many holders are reassessing what they are paying for.
• Recent news coverage has discussed Abbott Laboratories within the broader market focus on large healthcare stocks and how investors are approaching companies with diversified product portfolios. These headlines help explain why sentiment around the stock price has shifted and why valuation is back in focus.
• On Simply Wall St's 6 point valuation check, Abbott Laboratories scores a 5 out of 6. The rest of this article will walk through what that means using different valuation approaches, then finish with a more complete framework for thinking about what the stock might be worth.

Approach 1: Abbott Laboratories Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting its future cash flows and discounting them back to today using a required rate of return. It is essentially a way of translating future cash into a single present value figure.

For Abbott Laboratories, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow is about $7.1b. Analyst and extrapolated projections used in the model show Free Cash Flow figures such as $8.6b in 2026 and $10.4b in 2028, with further projections out to 2035 supplied by Simply Wall St as part of its 10 year FCF forecast set.

Running these cash flows through the DCF model produces an estimated intrinsic value of about $135.30 per share. Against the recent share price of $87.01, this implies Abbott Laboratories is trading at a 35.7% discount to that estimate, which points to a stock that screens as materially undervalued on this method.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Abbott Laboratories is undervalued by 35.7%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Abbott Laboratories Price vs Earnings

For profitable companies, the P/E ratio is a useful gauge because it links what you are paying directly to the earnings the business is currently generating. A higher or lower P/E often reflects what the market is factoring in for future growth and how risky those earnings might be, so a “normal” or “fair” P/E usually sits higher for businesses with stronger growth prospects and lower perceived risk.

Abbott Laboratories currently trades at a P/E of 24.2x. This sits close to the Medical Equipment industry average P/E of 24.1x, and below the peer group average of 33.2x. Simply Wall St’s “Fair Ratio” for Abbott Laboratories is 30.4x, which is its view of what a reasonable P/E could look like once factors such as earnings growth, industry, profit margins, market cap and company specific risks are taken into account.

The Fair Ratio aims to be more tailored than a simple comparison to industry or peer averages because it adjusts for those company specific characteristics instead of assuming all stocks in the group deserve the same P/E. With Abbott Laboratories on 24.2x versus a Fair Ratio of 30.4x, the stock screens as trading below that fair value benchmark on this approach.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Abbott Laboratories Narrative

Earlier we mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story about Abbott Laboratories to the numbers by connecting your view of its future revenue, earnings and margins to a forecast and a fair value. You can then compare that fair value to the current share price to help with buy or sell decisions. Each Narrative is hosted on the Community page and updates automatically when fresh information such as news or earnings is added. One investor might see Abbott as a resilient, diversified healthcare company and set a higher fair value closer to the US$118.64 analyst consensus. Another might focus on legal, regulatory and pricing risks and anchor nearer the lower US$92.00 estimate. Both views are captured transparently in their Narratives for others to review and challenge.

Do you think there's more to the story for Abbott Laboratories? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.